Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong near-term catalyst stack: FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on 2026-04-30/05-01, Q1 2026 product revenue rose 57% YoY to $191.2M, NDA submitted for AXS-12, SUNOSI patent settlement extended protection, and the stock is up about 33% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: • Oversold rebound • Range-bound action • Resistance failure Support Level: $236-$237 Resistance Level: $249-$250 Over the last month, AXSM has been range-bound and volatile, rebounding from an oversold drop to $221.64 but still needing a reclaim of $249-$250 to confirm upside.
Sentiment & News
Key News Insights: • Pediatric ADHD • NDA accepted • Earnings ahead Axsome's near-term outlook improved on pediatric ADHD trial starts and FDA acceptance of AXS-12 for narcolepsy cataplexy, with upcoming earnings and late-stage catalysts keeping the stock event-driven.
AI Summary
AXSM is evolving from a single-product biotech into a credible commercial CNS platform with 57% Q1 revenue growth and an expanded AUVELITY addressable market, but the stock now hinges on whether management can keep executing fast enough to justify a valuation that already reflects much of this progress.
Description
Axsome Therapeutics is a U.S.-based biopharmaceutical company developing treatments for central nervous system disorders. Its late-stage pipeline includes a depression candidate (AXS-05) with additional trials in Alzheimer's-related agitation and prior smoking cessation data, a migraine treatment that completed Phase III testing (AXS-07), and Phase III programs for narcolepsy (AXS-12) and fibromyalgia (AXS-14). The company has a research collaboration with Duke University and was founded in 2012 in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 5 | May 12 | AXSM | Axsome Therapeutics, Inc. | Strong near-term catalyst stack: FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on 2026-04-30/05-01, Q1 2026 product revenue rose 57% YoY to $191.2M, NDA submitted for AXS-12, SUNOSI patent settlement extended protection, and the stock is up about 33% over 21 trading days. | Closed | +0.4% |
| Jan 1 | Jan 8 | AXSM | Axsome Therapeutics, Inc. | Axsome Therapeutics is a hot idea with key upcoming FDA priority review of AXS-05 and NDA filing for AXS-12, strong Q3 revenue growth, and robust technical momentum. Despite operating losses and governance risks, its near-term regulatory catalysts provide potential for significant short-term price appreciation. | Closed | -8.3% |